Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2016

View Archived Issues

Apeptico and Mediolanum sign a cooperation and license agreement for solnatide

Amgen and Allergan submit MAA for bevacizumab biosimilar

Ferring Pharmaceuticals and MetaboGen enter research collaboration

Noveome Biotherapeutics begins phase II study of ST-266

BFORE study of bosutinib in CML meets primary endpoint

Purdue Pharma, AnaBios to study compounds for chronic pain

Calimmune and Cincinnati Children's Hospital Medical Center to work together on gene therapies

NeuroDerm gives update on ND-0612 regulatory path

Matinas BioPharma initiates dosing in phase I study of MAT-2501

Adaptimmune starts study of NY-ESO SPEAR-engineered T cells in myxoid/round cell liposarcoma

Promising phase I data presented for SEP-363856 in schizophrenia

Phase II data for verinurad plus febuxostat in patients with gout and asymptomatic hyperuricemia

Omeros provides continued access to OMS-721 for patient with HSCT-TMA

Novo Nordisk submits applications in E.U., U.S. for semaglutide

Sanofi Genzyme begins phase III study of isatuximab

Anti-APRIL monoclonal antibody developed at Visterra for IgA nephropathy

Novogen initiates phase I study of Cantrixil in ovarian cancer

TherapeuticsMD discloses topline results from Replenish trial of TX-001HR

VCN Biosciences' adenovirus expressing hyaluronidase: first clinical data

Further phase I data reported for DS-6051b in patients with solid tumors

Sage expedites development of SAGE-547 for postpartum depression

FDA grants fast track designation to Neovacs' IFN-alpha kinoid in lupus

Harvard College divulges novel CDK8 and/or CDK19 inhibitors

European Commission approves Lucentis for sixth indication

Takeda describes new Toll-like receptor 4 antagonists

The University of Athens identifies novel E-NPP 2 inhibitors

Beijing Institute of Pharmacology and Toxicology patents CB1 receptor antagonists

Shanghai Institute Materia Medica presents new c-Met inhibitors

FDA approves Avastin for platinum-sensitive ovarian cancer

WHO recommends seladelpar as INN for CymaBay's MBX-8025

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...